Table 4 |
|||||
|
Predicted epitopes for HLA DRB1*0101 and HLA DRB1*0401 which were changed by nonsynonymous mutations |
|||||
| Patient |
Amino acid start position |
Predicted core epitope (before mutation) |
Predicted -logIC50 (M) |
New epitope with amino acid changea |
New predicted -logIC50 (M) |
|
|
|||||
| HLA DRβ*0101 |
|||||
| RA313 |
274 |
RTAYPRFRY |
6.661 |
RTAHPRFRY |
6.896 |
| RA307 |
99 |
NLGLLFILA |
6.51 |
SLGLLFILA |
6.549 |
| OA302 |
215 |
YAAGPFALF |
6.681 |
YAAGPFALS |
5.708 |
| HLA DRβ*0401 |
|||||
| RA307 |
259 |
FVTKTLLLT |
7.329 |
FVAKTLLLT |
7.316 |
| RA313 |
88 |
PLPMPNPLV |
7.093 |
PLPIPNPLV |
6.946 |
| RA307 |
93 |
NPLVNLNLG |
7.09 |
NPLVNLSLG |
7.148 |
|
|
|||||
|
aBold indicates amino acid changed by mutation; a -logIC50 value above 6.5 is considered to be a binder for prediction purposes. IC50, median inhibitory concentration. |
|||||
|
Da Sylva et al. Arthritis Research & Therapy 2005 7:R844 doi:10.1186/ar1752 |
|||||
